Figure 5.
Metabolic and signaling effects upon acute MB1-47 treatment of leukemic mice in vivo. (A) Schematic illustration of acute exposure to MB1-47 in vivo via gavage (detailed in “Methods”). (B) Significantly altered metabolites after acute exposure to MB1-47, ranked by P value (−log2 transformed). (C) Ratio of pyruvate/lactate abundances from leukemic spleens after acute treatment with MB1-47 in vivo (mean ± SD). (D) Relative abundance of the indicated metabolites in leukemic spleens after acute treatment with MB1-47 in vivo. (E) Immunoblot analyses of cleaved PARP in leukemic spleens after acute treatment with MB1-47 in vivo. (F) Immunoblot analyses of AMPK, ACC, and 4E-BP1 in leukemic spleens after acute treatment with MB1-47 in vivo. Statistical significance (P) was determined by using the 2-tailed Student t test. **P < .01; ***P < .005.

Metabolic and signaling effects upon acute MB1-47 treatment of leukemic mice in vivo. (A) Schematic illustration of acute exposure to MB1-47 in vivo via gavage (detailed in “Methods”). (B) Significantly altered metabolites after acute exposure to MB1-47, ranked by P value (−log2 transformed). (C) Ratio of pyruvate/lactate abundances from leukemic spleens after acute treatment with MB1-47 in vivo (mean ± SD). (D) Relative abundance of the indicated metabolites in leukemic spleens after acute treatment with MB1-47 in vivo. (E) Immunoblot analyses of cleaved PARP in leukemic spleens after acute treatment with MB1-47 in vivo. (F) Immunoblot analyses of AMPK, ACC, and 4E-BP1 in leukemic spleens after acute treatment with MB1-47 in vivo. Statistical significance (P) was determined by using the 2-tailed Student t test. **P < .01; ***P < .005.

Close Modal

or Create an Account

Close Modal
Close Modal